Schizophrenia Studies


The reason for this study is to find out the potential benefits and safety of aripiprazole (Abilify®). Participants are eligible if between the ages of 13 and 17 and they have been diagnosed with schizophrenia or have shown symptoms of schizophrenia. Participation could last between 60 to 89 weeks, and could include up to 50 visits and 33 phone calls for the entire duration of the research study.